IDP:ETR
Biogen Inc
€226.35
arrow_upward
+1.48%(+3.30) 1D
Nov 5, 1:17:57 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IDP...
Open
€226.40
High
€229.25
Low
€226.35
Mkt. cap
37.61B
Avg. vol.
117.00
Volume
500.00
52-wk high
€231.10
52-wk low
€129.55
No. of employees
8K
Open
€226.40
High
€229.25
Low
€226.35
Mkt. cap
37.61B
Avg. vol.
117.00
Volume
500.00
52-wk high
€231.10
52-wk low
€129.55
No. of employees
8K
News stories
From web sources and news partners
Yahoo Finance Singapore
·
4 hours ago
Is Alzheimer’s Data Altering The Investment Case For Biogen (BIIB)?
Investing.com
·
2 days ago
Guggenheim raises Biogen stock price target to $300 on growth portfolio strength
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Industry-
Websitebiogen.com